# Trevi Therapeutics, Inc. > Clarifo company profile — qualitative business description generated from > the company's filings. Financial statements, charts and ratios are > available on Clarifo (https://www.clarifo.com/en/companies/Trevi Therapeutics, Inc.). ## Overview Trevi Therapeutics, Inc. is a U.S.-based biopharmaceutical company focused on developing Haduvio, an oral therapy for chronic cough and related respiratory conditions. The company’s work centers on clinical development, regulatory approval, and eventual commercialization of Haduvio in the United States and through partners outside the U.S. ## Products & services • Haduvio oral therapy for chronic cough • Development for chronic cough in IPF • Development for chronic cough in non-IPF ILD • Development for refractory chronic cough (RCC) • Clinical and regulatory development services for Haduvio - **Haduvio clinical development** (100%) — Clinical-stage development of Haduvio across respiratory cough indications. - **Regulatory and approval pathway** (0%) — Activities supporting FDA and other regulatory submissions for Haduvio. - **Future commercialization** (0%) — Planned U.S. and ex-U.S. commercialization of approved Haduvio products. - Haduvio oral therapy for chronic cough - Development for chronic cough in IPF - Development for chronic cough in non-IPF ILD - Development for refractory chronic cough (RCC) - Clinical and regulatory development services for Haduvio ## Customers Trevi does not currently sell commercial products; its eventual customers would be physicians, patients, and payors in respiratory disease markets. If approved, Haduvio would be prescribed by pulmonologists and other specialists treating IPF, non-IPF ILD, or refractory chronic cough, with reimbursement decisions made by third-party payors. Outside the U.S., commercialization would likely rely on collaboration or distribution partners rather than a direct sales force. - **Pulmonologists** (primary) — Specialists who would prescribe Haduvio for IPF and non-IPF ILD-related chronic cough. - **Refractory chronic cough specialists** (primary) — Pulmonologists and allergists treating RCC patients who have failed other therapies. - **Third-party payors** (primary) — Insurers and government payors that decide coverage and reimbursement levels. - **Patients with chronic cough** (primary) — End users of the therapy, especially those with IPF, non-IPF ILD, or RCC. - **Ex-U.S. commercial partners** (secondary) — Potential collaborators that would help market and distribute Haduvio outside the U.S. - Pulmonologists treating IPF and non-IPF ILD patients - Specialists treating refractory chronic cough patients - Patients needing prescription therapy for chronic cough - Third-party payors that determine coverage and reimbursement - Potential ex-U.S. commercialization partners and distributors ## Geography Trevi is headquartered in the United States and expects initial commercialization of Haduvio to be U.S.-focused. The company also expects to use third-party collaboration, distribution, and marketing arrangements outside the U.S., which makes international reach dependent on partners and local regulatory approvals. Its clinical and commercial exposure is therefore concentrated in the U.S., with future expansion tied to ex-U.S. partnering. - Headquartered in the United States - Planned initial commercialization is U.S.-focused - Ex-U.S. sales would likely rely on third-party partners - Regulatory approval is needed in each target market - Global expansion depends on local reimbursement and market access ## Strategy Trevi’s strategy is to advance Haduvio through late-stage clinical development, secure regulatory approval, and build a focused specialty commercial model in the U.S. The company is also pursuing intellectual property protection, manufacturing readiness, and reimbursement access while using partners for markets outside the U.S. Its near-term direction is defined by clinical execution and capital allocation to support multiple cough indications. - **Complete late-stage clinical development of Haduvio** (short-term) — Approval depends on demonstrating safety and efficacy in target cough populations. - **Prepare for U.S. commercialization** (medium-term) — A focused specialty sales model is needed if the product is approved. - **Secure reimbursement and market access** (medium-term) — Coverage and reimbursement will determine whether the product can be adopted at scale. - **Protect intellectual property and supply chain readiness** (long-term) — Patent protection and reliable manufacturing support long-term commercial value. - Advance Haduvio through Phase 3 and supportive studies - Pursue FDA approval for cough in IPF, non-IPF ILD, and RCC - Build a focused U.S. specialty sales force if approved - Use partners for ex-U.S. commercialization - Protect patents and regulatory exclusivity - Secure reimbursement and payer access ## Risks Trevi is a clinical-stage company with no product sales, so its value depends on successful development, approval, and commercialization of Haduvio. Key risks include clinical trial failure, regulatory delays, reimbursement uncertainty, manufacturing dependence on third parties, and the need for substantial additional capital. As with most biopharma developers, patent protection, safety findings, and market acceptance are also critical to future success. - **Clinical development failure** [critical] — Haduvio must prove safety and efficacy across target cough indications before approval. - **Regulatory approval risk** [high] — FDA and other authorities may require more data, delay approval, or reject applications. - **Financing risk** [high] — The company expects to fund operations through external capital until product revenue exists. - **Reimbursement and pricing risk** [high] — Payors may restrict coverage or require pricing concessions, limiting adoption. - **Manufacturing and third-party dependence** [medium] — Drug substance and finished product supply rely on external vendors and cGMP compliance. - **Intellectual property risk** [medium] — Patent scope, validity, and foreign protection affect exclusivity and long-term value. - No product revenue until Haduvio is approved and commercialized - Clinical trials may fail to show sufficient safety or efficacy - Regulatory approval timing is uncertain - Coverage and reimbursement may be limited or delayed - Third-party manufacturing and supply chain dependence - Additional capital will likely be needed ## Accounting Trevi’s reported results are dominated by research and development expense, which is largely driven by outsourced clinical trial work, CRO fees, and contract manufacturing costs. Because the company is pre-revenue and clinical-stage, estimates around accrued clinical trial costs, stock-based compensation, leases, and marketable securities can materially affect quarterly results and cash flow presentation. Future commercialization would also introduce revenue recognition, payer deductions, and launch-related judgments that are not yet present in the income statement. - **Research and development accruals** — Can shift reported R&D expense between periods - **Stock-based compensation** — Affects operating loss and non-cash reconciliation - **Marketable securities valuation** — Can affect reported investment gains/losses - **Lease accounting** — Affects balance sheet and operating expense presentation - **Future revenue recognition and deductions** — Will affect net product revenue and margins - R&D expense is driven by outsourced clinical trial and manufacturing costs - Accruals for CRO work affect period expense timing - Stock-based compensation is a meaningful non-cash expense - Marketable securities create fair value and accretion effects - Future product sales would introduce revenue recognition and payer estimates --- *Last updated: 2026-04-29T05:04:24.179446+00:00*